Actinium Pharmaceuticals Inc.
ATNM | AMEX
$1.20
$0 (0.00%)
Sep 22, 2026, 11:41 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 90K | n/a | 81K | 1.03M | 1.14M | n/a |
Cost of Revenue | n/a | 811K | n/a | n/a | 524K | 447K |
Gross Profit | 90K | -811K | 81K | 1.03M | 620K | -447K |
Operating Income | -36.25M | -42.12M | -51.92M | -34.1M | -24.96M | -22.39M |
Interest Income | 2.36M | 3.88M | 3.1M | 1.09M | 190K | 178K |
Pretax Income | -33.89M | -38.24M | -48.82M | -33.02M | -24.77M | -22.22M |
Net Income | -33.89M | -38.24M | -48.82M | -33.02M | -24.77M | -22.22M |
Selling & General & Admin | 15.21M | 12.08M | 13.33M | 12M | 8.08M | 6.31M |
Research & Development | 21.12M | 30.05M | 38.67M | 23.14M | 17.51M | 16.09M |
Other Expenses | n/a | -811K | n/a | n/a | n/a | -447K |
Operating Expenses | 36.34M | 41.31M | 52M | 35.13M | 25.58M | 21.95M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 36.34M | 42.12M | 52M | 35.13M | 26.11M | 22.39M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 31.2M | 30.07M | 26.6M | 24.14M | 20.57M | 12.13M |
Shares Outstanding (Diluted) | 31.2M | 30.07M | 26.6M | 24.14M | 20.57M | 12.13M |
EPS (Basic) | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 |
EPS (Diluted) | -1.09 | -1.27 | -1.83 | -1.37 | -1.20 | -1.83 |
EBITDA | -33.07M | -37.43M | -48.03M | -32.32M | -24.25M | -21.77M |
EBIT | -33.89M | -38.24M | -48.82M | -33.02M | -24.77M | -22.22M |
Depreciation & Amortization | 821K | 811K | 790K | 699K | 524K | 447K |
Add to Watchlist
Select watchlists to add or remove ATNM